Call for Special Issue Papers: Immunotheranostics,hic sunt leones !

Cancer Biotherapy and Radiopharmaceuticals is pleased to announce a special issue on Immunotheranostics, hic sunt leones!

In 2011 the Food and Drug Administration announced the approval of the first immune check point inhibitor, ipilumumab, for the treatment of unresectable or metastatic melanoma. Since then, the therapeutic approach consisting in unleashing a pre-existing immune response against the tumor has been extended to many cancer patients subgroups (e.g. lung cancer, lymphoma, hepatocellular carcinoma, etc…) and novel drugs have been implemented in clinical practice. Nevertheless, although the impressive advances achieved in the field, only a minority of patients responds to immunotherapy. In this scenario, molecular imaging with recently introduced radiopharmaceuticals holds the promise to allow an in vivo detection of biomarkers predictive of response, suitable both for patients' selection and monitoring during treatment, according to the so-called “theranostic” approach. Furthermore, several efforts have been made to develop combination strategies of immune check-point blockade with chemotherapy or radiation therapy.

Potential topics include but are not limited to:

Experimental studies aimed to detect targetable molecular signatures involved in cancer immunoevasion

Pre-clinical and clinical studies on novel radiopharmaceuticals directed towards immunotherapy-associated targets

Pre-clinical and clinical studies on novel combination between immunotherapy and other therapeutic strategies (radiation, chemotherapy, targeted therapy)

Molecular imaging for monitoring immunotherapy response and immune-related adverse events

Original articles, short articles or technical notes, and review articles will be considered.

All manuscripts will undergo a meaningful scrutiny and peer review by eminent experts in the field. Editing and publishing will of course meet very high standards.

Please submit your manuscripts by July 31, 2022. Contributions will receive prompt and thorough peer review. Please refer to our Instructions for Authors before submitting your manuscript for consideration.

Please direct Editorial questions to our Editor-in-Chief, Dr. Martin Brechbiel at mbrechbiel@liebertpub.com or to Dr. Luca Filippi at l.filippi@ausl.latina.it

Visit the Instructions for Authors:

www.liebertpub.com/cbr

Submit your paper for peer review online:

https://mc.manuscriptcentral.com/cancerbiotherapy